The Pharma Data

JANUARY 6, 2021

Founded in 2015, Standigm has raised $23M from leading investors and developed an elite team with multi-disciplinary expertise in chemistry, biology, pharmacology, artificial intelligence, and data structures to ease the pains of patients all over the world.

FDA Approval 52

FDA Approval FDA Drugs Science 52

The Pharma Data

MARCH 31, 2023

” Narcan nasal spray was first approved by the FDA in 2015 as a prescription drug. We encourage the manufacturer to make accessibility to the product a priority by making it available as soon as possible and at an affordable price.”

FDA Approval 40

FDA Approval FDA Production Drugs 40

The Pharma Data

JUNE 18, 2021

Food and Drug Administration (FDA) has approved PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older. Following today’s FDA approval, the U.S.

Vaccine 52

Vaccine FDA Approval FDA Disease 52

The Pharma Data

JULY 29, 2021

First approved in 2015 for severe eosinophilic asthma (SEA), mepolizumab is the first-in-class monoclonal antibody that targets IL-5. The resultant swellings can grow in both nostrils (bilateral) greatly impacting a patient due to various symptoms including nasal obstruction, loss of smell, facial pressure and nasal discharge.

FDA Approval 52

FDA Approval Clinical Trials FDA Treatment 52

FDA Law Blog: Biosimilars

FEBRUARY 27, 2024

156, a patent may be extended only once (even if it would be eligible for extension on more than one occasion because it applies to several FDA-approved products), and only one patent may be extended for each regulatory review period. RE 44,638 and with respect to each NDA approval, See FDA Docket Nos.

FDA Approval 59

FDA Approval FDA Production Therapies 59

The Pharma Data

JANUARY 6, 2021

Amgen won the first and only Food and Drug Administration (FDA) approval for an oncolytic viral therapy, for its first-generation modified HSV Imlygic (talimogene laherparepvec), approved for melanoma in 2015. Oncorus’ stock opened at $32.45 Monday, up $0.28 from the market close last Thursday. Most Read Today.

Virus 52

Virus FDA Approval Clinical Trials Trials 52

Drug Target Review

JUNE 21, 2023

Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. 2015 Sep 29;6:8382. 2015 Nov 19;163(5):1204-1213. Epub 2015 Nov 12. Why Clinical Trials Stop: The Role of Genetics. medRxiv; 2023. DOI: 10.1101/2023.02.07.23285407. Ochoa D, Karim M, Ghoussaini M, Hulcoop DG, McDonagh EM, Dunham I.

Disease 111

Disease Clinical Trials Therapies Science 111

The Pharma Data

JUNE 17, 2022

The adalimumab reference medicine (Humira ®* ) was first approved with an adalimumab concentration of 50 mg/mL. 2,3 In 2015, the EMA and US FDA approved Humira ® HCF, which contains adalimumab at a concentration of 100 mg/mL.

Biosimilars 52

Biosimilars Pharmacokinetics FDA Approval Packaging 52

Molecule Blog

AUGUST 13, 2021

If successful, this work could result in the repurposing of several FDA-approved therapeutics for the purpose of extending the human lifespan, at a lower cost and over faster timelines than conceivably possible with de novo drug discovery. The Scheibye-Knudsen lab has analyzed 1.5 billion prescriptions from 4.8

FDA Approval 52

FDA Approval DNA Small Molecule FDA 52

FDA Law Blog: Biosimilars

FEBRUARY 29, 2024

The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval. If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug. Patent Nos.

FDA 59

FDA Production FDA Approval Licensing 59

The Pharma Data

APRIL 4, 2023

The adalimumab reference medicine (Humira ® *) was first approved with an adalimumab concentration of 50 mg/mL. 1 In 2015, the EMA and US FDA approved Humira ® HCF, which contains adalimumab at a concentration of 100 mg/mL.

Biosimilars 40

Biosimilars Pharmacokinetics FDA Approval Packaging 40

The Pharma Data

JUNE 28, 2021

The Breakthrough Therapy designation aims to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over already available therapies that have received full FDA approval.

Therapies 40

Therapies Disease Treatment FDA Approval 40

Dark Matter Blog

AUGUST 27, 2020

In early August, risdiplam, an orally available small molecule that binds to a stem-loop structure in the SMN2 pre-mRNA, received FDA approval for the treatment of spinal muscular atrophy , a devastating genetic disease. The agent, onasemnogene abeparvovec, was approved by the FDA in 2019 and is marketed as Zolgensma.

Small Molecule 52

Small Molecule RNA Clinical Trials Drugs 52

Drug Target Review

OCTOBER 17, 2024

This year we completed investigational new drug (IND) enabling studies of ONC-841, which is an antagonist of Siglec-10, and received US Food and Drug Administration (FDA) approval for first-in-human study (FIH) in patients with solid tumours. The first patient has been dosed in the last quarter.

Immune Response 52

Immune Response Clinical Trials Trials Therapies 52

Drug Target Review

AUGUST 29, 2024

MR : Chimeric antigen receptor T-cell (CAR-T) therapy is very effective in treating patients with B-cell lymphoma, leukemia, and multiple myeloma, where we have six FDA-approved drugs. What potential advantages does the CD5 modulation strategy offer over traditional CAR-T therapies?

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

NIH Director's Blog: Drug Development

JULY 20, 2017

The first major advance in molecularly targeted drug treatment for the disease came in 2012, when the Food and Drug Administration (FDA) approved ivacaftor (Kalydeco). The next major milestone on the therapeutic pathway was the FDA’s approval in 2015 of Orkambi, a drug that combines ivacaftor with lumacaftor, the first “corrector”.

Clinical Trials 52

Clinical Trials Small Molecule Therapies Disease 52

The Pharma Data

AUGUST 17, 2021

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China. Yervoy is approved for unresectable or metastatic melanoma in more than 50 countries.

Treatment 52

Treatment Immune Response Trials FDA Approval 52

The Pharma Data

NOVEMBER 23, 2020

Food and Drug Administration (FDA) approved the combination of ipilimumab and nivolumab (Yervoy and Opdivo) for the first-line treatment of MPM based on mOS of 18.1 months (Baas 2020), and this is expected to serve as a benchmark for further approvals. .” Recently, the U.S. References.

Trials 40

Trials FDA Approval Treatment Virus 40

Metabolite Tales Blog

MAY 12, 2023

In 2021, almost one third of FDA approved drugs contained at least one fluorine. ACS Medicinal Chemistry Letters 2015 6 (8), 925-929, [link] [11] Kinesin Spindle Protein (KSP) Inhibitors. Xiaojing Wang, Minghua Sun, Connie New, Spencer Nam, Wesley P. Blackaby, Alastair J. Hodges, David Nash, Mizio Matteucci, Joseph P.

Drugs 52

Drugs Small Molecule FDA Approval Metabolic Stability 52

The Pharma Data

JUNE 30, 2021

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China. 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

Treatment 52

Treatment Trials FDA Approval Disease 52

Advarra

JULY 19, 2022

The sponsor-initiated IND is conducted by a pharma company seeking commercial approval. Q: When you want to do a study of an FDA-approved drug under an investigational indication, is an IND still required or can you seek an exemption? A: For FDA 1572 is a Statement of Investigator under US Regulations/Laws.

Packaging 52

Packaging FDA Trials Regulations 52

The Pharma Data

APRIL 11, 2021

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China. 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

Trials 52

Trials Treatment Clinical Trials Immune Response 52

The Pharma Data

SEPTEMBER 8, 2021

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China. Yervoy is approved for unresectable or metastatic melanoma in more than 50 countries.

Research 52

Research Immune Response Treatment Trials 52

The Pharma Data

MARCH 2, 2021

Food and Drug Administration (FDA), but has been authorized by FDA through an Emergency Use Authorization (EUA) for active immunization to prevent Coronavirus Disease 2019 (COVID-19) in individuals 18 years of age and older. There is no FDA-approved vaccine to prevent COVID-19.

Vaccine 52

Vaccine Clinical Trials FDA Trials 52

Codon

MARCH 28, 2023

The recipient rat was able to perform a task, which normally took eight weeks to learn, in seconds, according to comments made by program manager, Geoff Ling, at a 2015 DARPA event. RAM, which launched in 2015, funded additional groups at the University of Pennsylvania and elsewhere. That had to help!

Engineering 52

Engineering Research Science FDA Approval 52

Agency IQ

SEPTEMBER 15, 2023

Until recently, the FDA relied on a monograph process through which firms could bring OTC drugs to market without FDA approval so long as it adhered to pre-set terms under the monograph. Four comments were submitted to the docket established for the 2015 Petition.

Science 40

Science FDA Clinical Trials Clinical Pharmacology 40

Agency IQ

JANUARY 19, 2024

Similarly, only one product in 2023 was recommended for approval under “ exceptional circumstances ” – Loargys. This approval type has always been uncommon – before the pandemic, this pathway was used just eight times between 2015 and 2019. [ See AgencyIQ’s analysis of this approval type from 2015-2021 here.]

Biosimilars 40

Biosimilars FDA Production Treatment 40

Agency IQ

JULY 8, 2024

During a House Energy and Commerce (E&C) Health Subcommittee meeting , Woodcock explained that certain medical gases have been used for so long in medicine that they actually predate the establishment of the FDA’s review practice and thus, were technically being used without any sort of FDA approval.

FDA 40

FDA Regulations Production Packaging 40

The Pharma Data

MARCH 11, 2021

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China. 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

Treatment 52

Treatment Trials Therapies FDA Approval 52

The Pharma Data

FEBRUARY 8, 2021

The recruitment period for the study spanned from December 2015 to July 2017. Food and Drug Administration (FDA) approval for nmCRPC on February 14, 2018 and was approved for mCSPC on September 17, 2019. ERLEADA ® received U.S. 2 To date, more than 10,000 patients worldwide have been treated with ERLEADA ®.

Treatment 52

Treatment Pharmaceutical Companies Therapies Pharmaceuticals 52

Agency IQ

MARCH 25, 2024

FDA addressed the expanding practice of drug compounding in 1992 by issuing a compliance policy guide that clarified that pharmacies which compounded products at certain scales, for certain purposes, or without FDA approval were clearly operating “outside the bounds of traditional pharmacy practice.”

FDA 40

FDA Pharmacy Drugs Production 40

The Pharma Data

JANUARY 29, 2021

Janssen has worked with BARDA since 2015 on innovative solutions for influenza, chemical, biological, radiation and nuclear threats and emerging infectious diseases such as Ebola. COV2-S (SARS-CoV-2 vaccine) FDA Approval History. Department of Health and Human Services (HHS). i] [link] [ii] The B.1.351 Posted: January 2021.

Vaccine 40

Vaccine Trials Pharmaceutical Companies Clinical Trials 40

Agency IQ

OCTOBER 6, 2023

While stimulant use disorder is increasing, there are currently no FDA-approved medications. According to the Substance Abuse and Mental Health Services Administration (SAMHSA), “between 2008 and 2015, amphetamine-related hospitalizations more than tripled, increasing from 55,447 instances to 206,180.

FDA 40

FDA Treatment Production Trials 40

Agency IQ

JANUARY 26, 2024

Such a situation is commonplace in the clinical trial realm, in which investigational drug products which are not already FDA approved are administered to patients. Under the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA) , the FDA also has some authority to extend MCM expiration dates.

Science 40

Science FDA Production Packaging 40

Agency IQ

JUNE 16, 2023

An update on the Medical Device Quality Management System Regulation : In February 2022, the FDA proposed a new rule which would effectively transition the agency away from its longstanding Quality System Regulation (QSR) in favor of the ISO 13485:2016 standard. Read our analysis of that rule here and here. ]

Regulations 40

Regulations FDA Science Production 40

The Pharma Data

JUNE 18, 2021

FDA approval for adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. 3 In August 2019 , RINVOQ received U.S. Available at: [link]. Available at: [link].

Treatment 40

Treatment Disease Therapies Clinical Trials 40

The Pharma Data

AUGUST 11, 2020

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China. 1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

Therapies 52

Therapies Trials Disease Treatment 52